MS-DRG 837Medical
Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC
Major Diagnostic Category 17·Grouped by diagnosis·FY 2027
MS-DRG 837 is a Medical Medicare Severity Diagnosis Related Group under Major Diagnostic Category 17 (MDC 17) with a Major Complication or Comorbidity (MCC). It maps to 36 ICD-10-CM diagnosis codes. For FY 2027 it carries a relative weight of 4.7124 with a geometric mean length of stay of 10 days and an arithmetic mean of 14.6 days. Hospitals use this grouping to determine reimbursement for inpatient stays under Medicare.
Advertisements
FY 2027 payment data
From Table 5 of the FY 2027 IPPS Final Rule (CMS).
- Relative weight:
- 4.7124 (payment multiplier vs. the average case (1.0))
- Geometric mean stay:
- 10 days (used for transfer payments)
- Average stay:
- 14.6 days (arithmetic mean)
- Post-acute transfer policy:
- No (not subject to it)
Diagnosis codes (36)
As the principal diagnosis, these ICD-10-CM codes can group to DRG 837. 100% of the codes listed are billable.
- C91.00Acute lymphoblastic leukemia not having achieved remission
- C91.01Acute lymphoblastic leukemia, in remission
- C91.02Acute lymphoblastic leukemia, in relapse
- C92.00Acute myeloblastic leukemia, not having achieved remission
- C92.01Acute myeloblastic leukemia, in remission
- C92.02Acute myeloblastic leukemia, in relapse
- C92.40Acute promyelocytic leukemia, not having achieved remission
- C92.41Acute promyelocytic leukemia, in remission
- C92.42Acute promyelocytic leukemia, in relapse
- C92.50Acute myelomonocytic leukemia, not having achieved remission
- C92.51Acute myelomonocytic leukemia, in remission
- C92.52Acute myelomonocytic leukemia, in relapse
- C92.60Acute myeloid leukemia with 11q23-abnormality not having achieved remission
- C92.61Acute myeloid leukemia with 11q23-abnormality in remission
- C92.62Acute myeloid leukemia with 11q23-abnormality in relapse
- C92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
- C92.A1Acute myeloid leukemia with multilineage dysplasia, in remission
- C92.A2Acute myeloid leukemia with multilineage dysplasia, in relapse
- C93.00Acute monoblastic/monocytic leukemia, not having achieved remission
- C93.01Acute monoblastic/monocytic leukemia, in remission
- C93.02Acute monoblastic/monocytic leukemia, in relapse
- C94.00Acute erythroid leukemia, not having achieved remission
- C94.01Acute erythroid leukemia, in remission
- C94.02Acute erythroid leukemia, in relapse
- C94.20Acute megakaryoblastic leukemia not having achieved remission
- C94.21Acute megakaryoblastic leukemia, in remission
- C94.22Acute megakaryoblastic leukemia, in relapse
- C94.40Acute panmyelosis with myelofibrosis not having achieved remission
- C94.41Acute panmyelosis with myelofibrosis, in remission
- C94.42Acute panmyelosis with myelofibrosis, in relapse
- C95.00Acute leukemia of unspecified cell type not having achieved remission
- C95.01Acute leukemia of unspecified cell type, in remission
- C95.02Acute leukemia of unspecified cell type, in relapse
- Z08Encounter for follow-up examination after completed treatment for malignant neoplasm
- Z51.11Encounter for antineoplastic chemotherapy
- Z51.12Encounter for antineoplastic immunotherapy
Procedure codes (10)
ICD-10-PCS procedures that can group a stay to DRG 837.
- 3E03002Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach
- 3E03302Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
- 3E04002Introduction of High-dose Interleukin-2 into Central Vein, Open Approach
- 3E04302Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach
- 3E05002Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach
- 3E05302Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
- 3E06002Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
- 3E06302Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach
- 3E0R302Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach
- 3E0S302Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach